Myriad Genetics, Inc.
(NASDAQ : MYGN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-2.13%199.081.3%$749.78m
GILDGilead Sciences, Inc.
-2.66%62.510.9%$372.82m
CELGCelgene Corporation
-1.80%93.991.3%$323.19m
ALXNAlexion Pharmaceuticals, Inc.
-6.61%115.332.0%$295.67m
ILMNIllumina, Inc.
-3.17%279.443.5%$272.03m
BIIBBiogen Inc.
-2.68%225.851.3%$258.17m
VRTXVertex Pharmaceuticals Incorporated
-2.20%180.181.9%$251.48m
EXASExact Sciences Corporation
-0.77%116.9624.1%$238.08m
REGNRegeneron Pharmaceuticals, Inc.
-2.77%286.852.6%$193.57m
AAgilent Technologies, Inc.
-3.01%69.581.6%$188.95m
SRPTSarepta Therapeutics, Inc.
-1.54%93.6114.7%$184.96m
BMRNBioMarin Pharmaceutical Inc.
-2.12%75.764.3%$97.12m
INCYIncyte Corporation
-4.27%81.912.5%$90.56m
GHDXGenomic Health, Inc.
-0.35%73.261.8%$81.69m
NBIXNeurocrine Biosciences, Inc.
0.36%97.595.0%$71.75m

Company Profile

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through Diagnostics and Other segments. The Diagnostics segment engages in the provision of testing and collaborative development of testing that is designed to asses a risk of developing a disease later in life of an individual. The Other segmeng provides products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake, UT.